Chemoprevention of squamous cell carcinoma of the head and neck

Current Opinion in Oncology

Volumn 19, Issue 3, 2007, Pages 180-187

  Wrangle, John M ^a   Khuri, Fadlo R ^a,b  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chemoprevention; Head and neck cancer; Oral premalignant lesions; Second primary tumors

Indexed keywords

ACETYLCYSTEINE; BEXAROTENE; CELECOXIB; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIGALLOCATECHIN GALLATE; ETRETINATE; ISOTRETINOIN; PROTEIN P16; PROTEIN P53; RETINOIC ACID RECEPTOR ALPHA; RETINOIC ACID RECEPTOR BETA; RETINOL; RETINOL PALMITATE; TRANSFORMING GROWTH FACTOR ALPHA;

ALCOHOL CONSUMPTION; CANCER INVASION; CANCER PREVENTION; CANCER RISK; CARCINOGENESIS; CELL CYCLE REGULATION; CELL PROLIFERATION; CIGARETTE SMOKING; CLINICAL TRIAL; ENZYME ACTIVATION; GENE MUTATION; GENETIC POLYMORPHISM; HEAD AND NECK CARCINOMA; HETEROZYGOSITY LOSS; HUMAN; LEUKOPLAKIA; MOLECULAR BIOLOGY; MOUTH CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SQUAMOUS CELL CARCINOMA; WART VIRUS;

ANTICARCINOGENIC AGENTS; CARCINOMA, SQUAMOUS CELL; CHEMOPREVENTION; CLINICAL TRIALS; COMBINED MODALITY THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; MOUTH NEOPLASMS; RETINOIDS; SMOKING CESSATION; TUMOR MARKERS, BIOLOGICAL;

EID: 34247170902     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3280f01026     Document Type: Review

References (97)

1. Kim KB, Khuri FR, Shin DM. Recent advances in the management of squamous cell carcinoma of the head and neck. Expert Rev Anticancer Ther 2001; 1:99-110.
2. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000; 50:7-33.
3. Leon X, Ferlito A, Myer CM 3rd, et al. Second primary tumors in head and neck cancer patients. Acta Otolaryngol 2002; 122:765-778.
4. Khuri FR, Kim ES, Lee JJ, et al. The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial. Cancer Epidemiol Biomarkers Prev 2001; 10:823-829.
5. Sporn MB, Dunlop NM, Newton DL, Smith JM. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Federation Proceedings 1976; 35:1332-1338.
6. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 1953; 6:963-968.
7. Vikram B. Changing patterns of failure in advanced head and neck cancer. Arch Otolaryngol 1984; 110:564-565.
8. Maestro R, Gasparotto D, Vukosavljevic T, et al. Three discrete regions of deletion at 3p in head and neck cancers. Cancer Res 1993; 53:5775-5779.
9. Shin DM, Kim J, Ro JY, et al. Activation of p53 gene expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 1994; 54:321-326.
10. Nees M, Homann N, Discher H, et al. Expression of mutated p53 occurs in tumor-distant epithelia of head and neck cancer patients: a possible molecular basis for the development of multiple tumors. Cancer Res 1993; 53:4189-4196.
11. Santos CR, Rodriguez-Pinilla M, Vega FM, et al. VRK1 signaling pathway in the context of the proliferation phenotype in head and neck squamous cell carcinoma. Mol Cancer Res 2006; 4:177-185.
12. Eberhart CE, Coffey RJ, Radhika A, et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107:1183-1188.
13. Yu H-P, Xu S-Q, Liu L, et al. Cyclooxygenase-2 expression in squamous dysplasia and squamous cell carcinoma of the esophagus. Cancer Lett 2003; 198:193-201.
14. Wilson KT, Fu S, Ramanujam KS, Meltzer SJ. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res 1998; 58:2929-2934.
15. Zimmermann KC, Sarbia M, Weber AA, et al. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 1999; 59:198-204.
16. Shiota G, Okubo M, Noumi T, et al. Cyclooxygenase-2 expression in hepatocellular carcinoma. Hepatogastroenterology 1999; 46:407-412.
17. Ristimaki A, Honkanen N, Jankala H, et al. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 1997; 57:1276-1280.
18. Chan G, Boyle JO, Yang EK, et al. Cyclooxygenase-2 expression is upregulated in squamous cell carcinoma of the head and neck. Cancer Res 1999; 59:991-994.
19. Lin DT, Subbaramaiah K, Shah JP, et al. Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer. Head Neck 2002; 24:792-799.
20. Subbaramaiah K, Altorki N, Chung WJ, et al. Inhibition of cyclooxygenase-2 gene expression by p53. J Biol Chem 1999; 274:10911-10915.
21. Kinugasa Y, Hatori M, Ito H, et al. Inhibition of cyclooxygenase-2 suppresses invasiveness of oral squamous cell carcinoma cell lines via down-regulation of matrix metalloproteinase-2 and CD44. Clin Exp Metastasis 2004; 21:737-745.
22. Gallo O, Franchi A, Magnelli L, et al. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia 2001; 3:53-61.
23. Wang Z, Fuentes CF, Shapshay SM. Antiangiogenic and chemopreventive activities of celecoxib in oral carcinoma cell. Laryngoscope 2002; 112:839-843.
24. Sartor M, Steingrimsdottir H, Elamin F, et al. Role of p16/MTS1, cyclin D1 and RB in primary oral cancer and oral cancer cell lines. Br J Cancer 1999; 80 (1-2):79-86.
25. Soni S, Kaur J, Kumar A, et al. Alterations of rb pathway components are frequent events in patients with oral epithelial dysplasia and predict clinical outcome in patients with squamous cell carcinoma. Oncology 2005; 68 (4-6):314-325.
26. Holley SL, Matthias C, Jahnke V, et al. Association of cyclin D1 polymorphism with increased susceptibility to oral squamous cell carcinoma. Oral Oncology 2005; 41:156-160.
27. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998; 92:725-734.
28. Cairns P, Mao L, Merlo A, et al. Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science 1994; 265:415-417.
29. Papadimitrakopoulou VA, Izzo J, Mao L, et al. Cyclin D1 and p16 alterations in advanced premalignant lesions of the upper aerodigestive tract: role in response to chemoprevention and cancer development. Clin Cancer Res 2001; 7:3127-3134.
30. van der Riet P, Nawroz H, Hruban RH, et al. Frequent loss of chromosome 9p21-22 early in head and neck cancer progression. Cancer Res 1994; 54:1156-1158.
31. Zhang SY, Klein-Szanto AJ, Sauter ER, et al. Higher frequency of alterations in the p16/CDKN2 gene in squamous cell carcinoma cell lines than in primary tumors of the head and neck. Cancer Res 1994; 54:5050-5053.
32. Grandis JR, Tweardy DJ. TGF-alpha and EGFR in head and neck cancer. J Cell Biochem Suppl 1993; 17F:188-191.
33. Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993; 53:3579-3584.
34. Beenken SW, Sellers MT, Huang P, et al. Transforming growth factor alpha (TGF-alpha) expression in dysplastic oral leukoplakia: modulation by 13-cis retinoic acid. Head & Neck 1999; 21:566-573.
35. Endo S, Zeng Q, Burke NA, et al. TGF-alpha antisense gene therapy inhibits head and neck squamous cell carcinoma growth in vivo. Gene Ther 2000; 7:1906-1914.
36. He Y, Zeng Q, Drenning SD, et al. Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from the U6 promoter. J Natl Cancer Inst 1998; 90:1080-1087.
37. Song JI, Lango MN, Hwang JD, et al. Abrogation of transforming growth factor-alpha/epidermal growth factor receptor autocrine signaling by an RXR-selective retinoid (LGD1069, Targretin) in head and neck cancer cell lines. Cancer Research 2001; 61:5919-5925.
38. Masuda M, Suzui M, Lim JTE, et al. Epigallocatechin-3-gallate decreases VEGF production in head and neck and breast carcinoma cells by inhibiting EGFR-related pathways of signal transduction. J Exp Ther Oncol 2002; 2:350-359.
39. Wolbach SB, Howe PR. Nutrition Classics. The Journal of Experimental Medicine 42: 753-77, 1925.
40. Tissue changes following deprivation of fat-soluble A vitamin. S. Burt Wolbach and Percy R. Howe. Nutr Rev 1978; 36:16-19.
41. Lotan R, Xu XC, Lippman SM, et al. Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin. N Engl J Med 1995; 332:1405-1410.
42. Sun SY, Lotan R. Retinoids and their receptors in cancer development and chemoprevention. Crit Rev Oncol Hematol 2002; 41:41-55.
43. Slebos RJ, Yi Y, Ely K, et al. Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma. Clin Cancer Res 2006; 12 (3 Pt 1):701-709.
44. Fakhry C, Gillison ML. Clinical implications of human papillomavirus in head and neck cancers. J Clin Oncol 2006; 24:2606-2611.
45. Berenson JR, Yang J, Mickel RA. Frequent amplification of the bcl-1 locus in head and neck squamous cell carcinomas. Oncogene 1989; 4:1111-1116.
46. Fukuzawa H, Kiyoshima T, Kobayashi I, et al. Transcription promoter activity of the human S100A7 gene in oral squamous cell carcinoma cell lines. Biochim Biophys Acta 2006; 1759 (3-4):171-176.
47. Haydon MS, Googe JD, Sorrells DS, et al. Progression of eIF4e gene amplification and overexpression in benign and malignant tumors of the head and neck. Cancer 2000; 88:2803-2810.
48. Sorrells DL, Ghali GE, Meschonat C, et al. Competitive PCR to detect eIF4E gene amplification in head and neck cancer. Head Neck 1999; 21:60-65.
49. Hibi K, Trink B, Patturajan M, et al. AIS is an oncogene amplified in squamous cell carcinoma. Proc Natl Acad Sci U S A 2000; 97:5462-5467.
50. McLaughlin PJ, Zagon IS. Progression of squamous cell carcinoma of the head and neck is associated with down-regulation of the opioid growth factor receptor. Int J Oncol 2006; 28:1577-1583.
51. Wang X, Pavelic ZP, Li Y, et al. Overexpression and amplification of glutathione S-transferase pi gene in head and neck squamous cell carcinomas. Clin Cancer Res 1997; 3:111-114.
52. Weed DT, Gomez-Fernandez C, Yasin M, et al. MUC4 and ErbB2 expression in squamous cell carcinoma of the upper aerodigestive tract: correlation with clinical outcomes. Laryngoscope 2004; 114 (8 Pt 2 Suppl 101):1-32.
53. Massarelli E, Brown E, Tran NK, et al. Loss of E-cadherin and p27 expression is associated with head and neck squamous tumorigenesis. Cancer 2005; 103:952-959.
54. Lee TL, Yeh J, Van Waes C, Chen Z. Epigenetic modification of SOCS-1 differentially regulates STAT3 activation in response to interleukin-6 receptor and epidermal growth factor receptor signaling through JAK and/or MEK in head and neck squamous cell carcinomas. Mol Cancer Ther 2006; 5:8-19. Epigenetic modification may become an important therapeutic target in oncology in general, and SCCHN in particular.
55. Lee JJ, Hong WK, Hittelman WN, et al. Predicting cancer development in oral leukoplakia: ten years of translational research. Clin Cancer Res 2000; 6:1702-1710.
56. Copper MP, Jovanovic A, Nauta JJ, et al. Role of genetic factors in the etiology of squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 1995; 121:157-160.
57. Foulkes WD, Brunet JS, Kowalski LP, et al. Family history of cancer is a risk factor for squamous cell carcinoma of the head and neck in Brazil: a case-control study. Int J Cancer 1995; 63:769-773.
58. Foulkes WD, Brunet JS, Sieh W, et al. Familial risks of squamous cell carcinoma of the head and neck: retrospective case-control study. BMJ 1996; 313:716-721.
59. Goldgar DE, Easton DF, Cannon-Albright LA, Skolnick MH. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst 1994; 86:1600-1608.
60. Lippman SM, Hong WK. Molecular markers of the risk of oral cancer. N Engl J Med 2001; 344:1323-1326.
61. Sturgis EM, Castillo EJ, Li L, et al. XPD/ERCC2 EXON 8 Polymorphisms: rarity and lack of significance in risk of squamous cell carcinoma of the head and neck. Oral Oncol 2002; 38:475-477.
62. Sturgis EM, Castillo EJ, Li L, et al. Polymorphisms of DNA repair gene XRCC1 in squamous cell carcinoma of the head and neck. Carcinogenesis 1999; 20:2125-2129.
63. Sturgis EM, Zheng R, Li L, et al. XPD/ERCC2 polymorphisms and risk of head and neck cancer: a case-control analysis. Carcinogenesis 2000; 21:2219-2223.
64. Minard CG, Spitz MR, Wu X, et al. Evaluation of glutathione S-transferase polymorphisms and mutagen sensitivity as risk factors for the development of second primary tumors in patients previously diagnosed with early-stage head and neck cancer. Cancer 2006; 106:2636-2644. As risk modeling becomes more important to selecting candidates for chemopreventive therapy, data such as these become increasingly relevant.
65. Sturgis EM, Wei Q. Genetic susceptibility: molecular epidemiology of head and neck cancer. Curr Opin Oncol 2002; 14:310-317.
66. Jahnke V, Matthias C, Fryer A, Strange R. Glutathione S-transferase and cytochrome-P-450 polymorphism as risk factors for squamous cell carcinoma of the larynx. American Journal of Surgery 1996; 172:671-673.
67. Hashibe M, Brennan P, Strange RC, et al. Meta- and pooled analyses of GSTM1, GSTT1, GSTP1, and CYP1A1 genotypes and risk of head and neck cancer. Cancer Epidemiol Biomarkers Prev 2003; 12:1509-1517.
68. Wu CL, Sloan P, Read AP, et al. Deletion mapping on the short arm of chromosome 3 in squamous cell carcinoma of the oral cavity. Cancer Res 1994; 54:6484-6488.
69. Rosin MP, Lam WL, Poh C, et al. 3p14 and 9p21 loss is a simple tool for predicting second oral malignancy at previously treated oral cancer sites. Cancer Res 2002; 62:6447-6450.
70. Mao L, El-Naggar AK, Papadimitrakopoulou V, I Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy. J Natl Cancer Inst 1998; 90:1545-1551.
71. Gross J, Fuchs J, Machulik A, et al. Apoptosis, necrosis and hypoxia inducible factor-1 in human head and neck squamous cell carcinoma cultures. Int J Oncol 2005; 27:807-814.
72. Miyamoto R, Uzawa N, Nagaoka S, et al. Prognostic significance of cyclin D1 amplification and overexpression in oral squamous cell carcinomas. Oral Oncol 2003; 39:610-618.
73. Hong WK, Endicott J, Itri LM, et al. 13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med 1986; 315:1501-1505.
74. Stich HF, Mathew B, Sankaranarayanan R, Nair MK. Remission of oral precancerous lesions of tobacco/areca nut chewers following administration of beta-carotene or vitamin A, and maintenance of the protective effect. Cancer Detect Prev 1991; 15:93-98.
75. Stich HF, Mathew B, Sankaranarayanan R, Nair MK. Remission of precancerous lesions in the oral cavity of tobacco chewers and maintenance of the protective effect of beta-carotene or vitamin A. Am J Clin Nutr 1991; 53 (1 Suppl):298S-304S.
76. Stich HF, Tsang SS. Promoting activity of betel quid ingredients and their inhibition by retinol. Cancer Lett 1989; 45:71-77.
77. Stich HF, Rosin MP, Hornby AP, et al. Remission of oral leukoplakias and micronuclei in tobacco/betel quid chewers treated with beta-carotene and with beta-carotene plus vitamin A. Int J Cancer 1988; 42:195-199.
78. Lippman SM, Batsakis JG, Toth BB, et al. Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N Engl J Med 1993; 328:15-20.
79. Papadimitrakopoulou VA, Hong WK, Lee JS, et al. Low-dose isotretinoin versus beta-carotene to prevent oral carcinogenesis: long-term follow-up. J Natl Cancer Inst 1997; 89:257-258.
80. Sankaranarayanan R, Mathew B, Varghese C, et al. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment. Oral Oncol 1997; 33:231-236.
81. Liede K, Hietanen J, Saxen L, et al. Long-term supplementation with alpha-tocopherol and beta-carotene and prevalence of oral mucosal lesions in smokers. Oral Dis 1998; 4:78-83.
82. Chiesa F, Tradati N, Marazza M, et al. Prevention of local relapses and new localisations of oral leukoplakias with the synthetic retinoid fenretinide (4-HPR). Preliminary results. Eur J Cancer B Oral Oncol 1992; 28B:97-102.
83. Lippman SM, Lee JJ, Martin JW, et al. Fenretinide activity in retinoid-resistant oral leukoplakia. Clin Cancer Res 2006; 12:3109-3114. Fenretinide may have activity in OPL despite retinoid resistance.
84. Chiesa F, Tradati N, Grigolato R, et al. Randomized trial of fenretinide (4-HPR) to prevent recurrences, new localizations and carcinomas in patients operated on for oral leukoplakia: long-term results. Int J Cancer 2005; 115:625-629.
85. Armstrong WB, Wan XS, Kennedy AR, et al. Development of the Bowman-Birk inhibitor for oral cancer chemoprevention and analysis of Neu immunohistochemical staining intensity with Bowman-Birk inhibitor concentrate treatment. Laryngoscope 2003; 113:1687-1702.
86. Mulshine JL, Atkinson JC, Greer RO, et al. Randomized, double-blind, placebo-controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clin Cancer Res 2004; 10:1565-1573.
87. Rudin CM, Cohen EE, Papadimitrakopoulou VA, et al. An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. J Clin Oncol 2003; 21:4546-4552.
88. Hong WK, Lippman SM, Itri LM, et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 1990; 323:795-801.
89. Benner SE, Pajak TF, Lippman SM, et al. Prevention of second primary tumors with isotretinoin in patients with squamous cell carcinoma of the head and neck: long-term follow-up. J Natl Cancer Inst 1994; 86:140-141.
90. Bolla M, Lefur R, Ton Van J, et al. Prevention of second primary tumours with etretinate in squamous cell carcinoma of the oral cavity and oropharynx. Results of a multicentric double-blind randomised study. Eur J Cancer 1994; 30A:767-772.
91. Jyothirmayi R, Ramadas K, Varghese C, et al. Efficacy of vitamin A in the prevention of loco-regional recurrence and second primaries in head and neck cancer. Eur J Cancer B Oral Oncol 1996; 32B:373-376.
92. van Zandwijk N, Dalesio O, Pastorino U, et al. EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the EUropean Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. J Natl Cancer Inst 2000; 92:977-986.
93. Khuri FR, Lee JJ, Lippman SM, et al. Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst 2006; 98:441-450. Our phase III study of 1384 patients failed to show that at a low, tolerable dose of isotretinoin second primary tumor development was inhibited. There was a transient protective effect against recurrence while patients were on the drug, but this was not significant. The most important finding was that continued smoking was associated with a higher likelihood of death from second primary tumors, primary tumor recurrence, or other smoking-related disease.
94. Khuri FR, Kim ES, Lee JJ, et al. The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial. Cancer Epidemiol Biomarkers Prev 2001; 10:823-829.
95. Perry CF, Stevens M, Rabie I, et al. Chemoprevention of head and neck cancer with retinoids: a negative result. Arch Otolaryngol Head Neck Surg 2005; 131:198-203.
96. Bairati I, Meyer F, Gelinas M, et al. A randomized trial of antioxidant vitamins to prevent second primary cancers in head and neck cancer patients. J Natl Cancer Inst 2005; 97:481-488.
97. Shin DM, Khuri FR, Murphy B, et al. Combined interferon-alfa, 13-cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial. J Clin Oncol 2001; 19:3010-3017.